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xerostomia were 13% and 17%, respectively. Tumor stage, unilateral 
neck irradiation, and tumor subsite (p<0.001) correlated with late 
toxicity. For the whole group, clinically relevant deterioration was 
seen on the QLQ-H&N35 dry mouth scale (-21, compared to baseline), 
while the scores on the QLQ-H&N35 swallowing were returned to 
baseline level. Unilateral neck irradiation was the most significant 
predictor for better scores on the QLQ-H&N35 dry mouth scale.  
Conclusions: Excellent outcomes were achieved in patients treated 
with 46 Gy of IMRT followed by a stereotactic body radiotherapy boost 
by means of the Cyberknife. No single failure was reported in patients 
with low tumor stage and HPV-related disease. This highly-conformal 
boost technique significantly reduced toxicity and improved QoL-
scores without jeopardizing outcomes. However, patient-reported 
xerostomia remains a major problem. Because unilateral neck 
irradiation was the most significant predictor for better scores on 
QLQ-H&N35 dry mouth scale, expanding the indications for this 
treatment approach needs to be thoroughly investigated in 
prospective trials. Given the increasing incidence of HPV-related OPC 
in the last decades especially among young patients, further reduction 
of the incidence of these troublesome complications is, therefore, 
mandatory.  
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Purpose/Objective: In radiation oncology 18F-FDG PET imaging has 
increasingly been investigated for prediction and monitoring of 
treatment response. The integrated SUV (iSUV) has been reported to 
be associated with treatment outcome in HNSCC. We investigated the 
predictive power of iSUV and its comparison with commonly used 18F-
FDG PET derived metrics (i. e. SUVmax, SUVmean), tumor volume and the 
TNM staging system in squamous cell carcinomas of the head and 
neck.  
Materials and Methods: Eightyone (cT1 – cT4) HNSCC patients treated 
with radiotherapy or chemo-radiation were included retrospectively. 
39 patients had a tumor of the larynx and 41 patients had an 
oropharynx tumor. All patients underwent an 18F-FDG-PET-CT scan for 
radiation treatment planning and the primary tumor was delineated 
by an experienced radiation oncologist on the fused images PET and 
CT images (Figure 1a). Basic SUV uptake metrics were extracted from 
the primary GTV, including SUVmax, SUVmean, and iSUV defined as the 
product of tumor volume and SUVmean. The non-parametric Mann-
Whitney U test and the log rank test were used to determine 
statistical significant differences on overall survival groups. For TNM 
the Chi-square test was used. Univariate Cox proportional-hazards 
models were used compared the risk of death among patients. A 5-
fold cross validated c-index was determined to evaluate the model’s 
performance. 
Results: The median survival time was 37 months (95% CI, 33-41 
months) and the median follow up was 30 months (range: 0.7-41), 
with an event rate of 28 %. iSUV was significantly associated with 
overall survival (p = 0.001) and showed a 5-fold cross validation c-
index of 0.78. The comparison with TNM and other evaluated 
parameters is summarized in Table 1. For comparison, Kaplan Meier 
curves are shown in Figure 1b.  
 
Table 1. Univariate association with overall survival 
 iSUV SUVmax SUVmean Tumor 
volume 
TNM 
Non-parametric test 
(p-value) 
0.001 0.011 0.080 0.000 0.135 
Log Rank test (p-
value) 
0.010 0.117 0.302 0.009 0.139 
C-index 0.78 0.70 0.62 0.77 0.68 
 
Conclusions: In line with previous findings, the integrated SUV is an 
important predictor of overall survival in HNSCC. The TNM staging 
system showed a limited value as prognostic factor. iSUV had a better 
prognostic performance than the most commonly used 18F-FDG-PET-CT 
derived metrics, however it was not a better predictor than tumor 
volume. Analysis of an extended cohort and a tumor anatomical sub-
location analysis will follow.  
   
PO-0662   
Planning according to plan: quality assurance in a randomized 
international multicenter phase II trial. 
J. Heukelom1, K. Nichol1, H. Bartelink1, O. Hamming1, E. Lamers1, C.R. 
Rasch2, M. Verheij1, J.J. Sonke1 
1The Netherlands Cancer Institute - Antoni van Leeuwenhoek 
Hospital, Radiotherapy Department, Amsterdam, The Netherlands  
2Academisch Medisch Centrum, Radiotherapy Department, 
Amsterdam, The Netherlands  
 
Purpose/Objective: Randomized controlled trials are the cornerstone 
of evidence-based medicine. Therefore, quality assurance (QA) of 
these trials is of vital importance. QA has various aspects, such as 
monitoring, image QA and treatment planning QA. We describe the 
latter aspect for a randomized international multicenter phase II trial 
for head and neck cancer: 'Adaptive and innovative Radiation 
Treatment FOR improving Cancer treatment outcomE (ARTFORCE)' 
(registered with ClinicalTrials.gov number NCT01504815).  
In ARTFORCE patients are randomized between chemoradiotherapy 
with concurrent cisplatin or Cetuximab and between standard 
radiotherapy (RT) and redistributed adaptive RT with a maximum dose 
up to 84Gy, resulting in four treatment arms (Figure 1). Because the 
planning of redistributed RT dose requires a novel approach, we will 
discuss its QA. 
 Materials and Methods: First, consensus was reached by the 
participating centers on delineation and treatment planning 
guidelines. A contouring atlas was made and dose objectives and 
constraints were set, which were subsequently used in the dummy 
run. For the dummy run, an anonymized CT scan and delineations 
were provided to all participating centers for treatment planning of 
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both RT regimens. Another anonymized CT was distributed for 
delineation purposes. Four pairs of treatment plans and five 
delineation sets were compared to the agreed constraints and 
evaluated by an expert panel. Furthermore, the delineations were 
quantitatively analyzed and compared to the derived median contour 
from all delineations. 
Results:  
Delineation 
The expert panel noted only minor protocol violations and approved 
all delineations. Quantitative analysis showed overall uniformity in 
contouring with mean distances to the median contour less than 3mm 
for 7 out of 11 OAR. The distance to median contour was largest for 
organs that extend in the cranial-caudal direction e.g. larynx and 
brainstem. 
Planning 
There were minor protocol violations for some organs at risk (OAR), 
due to the preference for tumor coverage. These violations were seen 
for submandibular gland (mean overdose 20.3Gy), inside PTV), 
mandible (mean overdose 3.3Gy, only in standard RT arm) and the 
right carotid artery (mean overdose 4.4Gy) and were seen in all 
analyzed treatment plans, for both RT regimens. In the redistributed 
radiotherapy arm, all guidelines for the tumor dose and dose 
redistribution were met successfully by all centers. This did not lead 
to more protocol violations for OAR. Due to the redistribution, the 
mean OAR dose in the experimental RT arm was on average 1.7Gy 
lower compared to the standard arm. 
Conclusions: The planning and contouring dummy run of the 
international ARTFORCE trial showed only minor protocol violations. 
Redistribution of dose to the tumor to a maximum of 84Gy did not 
lead to extra dose for organs at risk. Due to consensus on guidelines, 
high planning and delineation uniformity was achieved. 
   
PO-0663   
Early density and volume variations of parotid glands are correlated 
with acute xerostomia during IMRT for HN cancer 
F. Ricchetti1, M.L. Belli2, G.M. Cattaneo2, E. Scalco3, S. Broggi2, G. 
Sanguineti1, G. Rizzo3, C. Fiorino2 
1Johns Hopkins University, Radiation Oncology, Baltimore MD, USA  
2San Raffaele Scientific Institute, Medical Physics, Milan, Italy  
3CNR, Istituto di Bioimmagini e Fisiologia Molecolare, Milan, Italy  
 
Purpose/Objective: Investigating if early volume and density changes 
of parotid glands (PGs) are correlated with acute xerostomia scores 
prospectively assessed in head-neck cancer (HNC) patients treated 
with IMRT.  
Materials and Methods: 24 HNC patients treated radically with RT (+ 
concomitant chemotherapy) to 58.1/70 Gy (median dose of tumor and 
nodes PTVs) in 35 fractions with a SIB approach were available for 
analysis. For each patient 5-9 kVCT images (median 7) were acquired. 
PGs contours, drawn on the first CT, were automatically propagated 
to the other images using a validated algorithm, based on a non-rigid 
image registration. The kinetics of PGs deformation was evaluated in 
terms of density and volume rate variation during the treatment (rΔρ 
[HU/day] and rΔvol [mm3/day]); in particular, density changes during 
treatment were previously reported by our group as a potential 
surrogate of acinar loss reduction and consequent increase of the 
fatty component in the PGs. Prospective assessment of acute 
xerostomia (CTCAE v.3.0) was performed weekly during the whole 
treatment (range: grade 1-4). For each patient, both the peak and the 
mean value of the score were considered. The correlation between 
acute xerostomia and PGs early rΔρ and rΔvol, during the first 2 weeks 
of treatment, was evaluated by the Man-Withney test and uni-variate 
logistic and ROC curve analysis (cut-off: median value for the mean 
acute xerostomia, grade 2 for peak score). Maximum, minimum and 
average values of the two PGs were separately considered for each 
patient.  
Results: Early rΔρ and rΔvol were not correlated with peak acute 
xerostomia while they were found to be significantly correlated with 
the mean acute score. The minimum change of the two PGs was the 
most predictive value, resulting in a rΔρ 1-2 [HU/day] equal to -0.98 
vs -0.22 (p=0.05) and rΔvol 1-2 [mm3/day] equal to -455 vs -127 
(p=0.03) for patients with mean acute xerostomia ≥ 1.57 or < 1.57, 
respectively. Early rΔρ and rΔvol result good predictors of the risk of 
mean acute xerostomia score > 1.57 (median value) in logistic uni-
variate analysis (rΔρ OR=0.11, p-value=0.01; rΔvol OR=0.10, p-
value=0.04), with a moderately high predictive values (rΔρ AUC=0.76, 
p-value=0.01; rΔvol AUC=0.77, p-value=0.01). Patients with a mean 
acute xerostomia > 1.57 show a significantly larger rΔρ and rΔvol at 
the begin of the treatment (Figure 1). On the other hand, rΔρ and 
rΔvol are smaller and almost constant during the treatment in patients 
with mean acute xerostomia score ≤ 1.57. 
Conclusions: Early PGs deformation, in terms of both rΔρ and rΔvol is 
correlated to the mean acute xerostomia during treatment. Although 
this result needs prospective confirmation on a larger population, it 
strongly supports the consideration of early density (and volume) 
variation as a pre-clinical sign of more adverse acute xerostomia 
symptoms. This information could be likely used to select patients 
that may benefit from ART and/or supportive therapy. 
 
 Figure 1 . Mean rates of density (rΔρ [HU/day]) and volume (rΔvol 
[mm3/day]) variations calculated on PGs versus the kVCT number, 
divided based on the median value of the mean acute xerostomia 
(1.57). 
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Purpose/Objective: The objective of this study was to evaluate the 
effect of curative radiation therapy (RT) on different domains of 
quality of life (QOL) in head and neck cancer patients depending on 
surgery prior to RT with or without concurrent chemotherapy (CRT). 
Materials and Methods: 129 patients with locally advanced head and 
neck cancer (LAHNC) completed the EORTC QLQ C30 and H&N 35 
questionnaires at the beginning (t0) and the end (t1) of radiation 
therapy, and 6-8 weeks after radiation therapy at first follow-up (t2). 
All patients received intensity modulated radiation therapy (IMRT) to 
a total dose of 60-70 Gy with conventional fractionation (2 Gy/d). The 
following domains were tested: Physical functioning, global quality of 
life, fatigue,nausea and vomiting, dry mouth, sticky saliva and 
swallowing. Statistical testing of radiation effects was performed 
using general linear models with repeated measures, adjusting for the 
effects of age, initial surgery and simultaneous chemotherapy. 
Results: Radiation therapy affects QOL significantly. In all domains 
but fatigue QOL decreased significantly between t0 and t1 and often 
recovered until t2, however dry mouth and sticky saliva stayed at high 
levels until t2. Significant effect modification with primary surgery 
were found at sticky saliva (p=0.02;figure 2) and swallowing 
(p=0.002), while there was only weak evidence for a joint effect with 
simultaneous chemotherapy in physical functioning (p=0.06) and 
global quality of life (p=0.09). 
Conclusions: Despite the use of IMRT, radiation therapy has a 
negative effect on several domains of quality of life but not on 
fatigue. Most of these effects are short-term with a significant 
recovery until 6-8 weeks after radiotherapy. After RT swallowing 
returns almost to baseline in patients who had prior surgery. While 
swallowing seems to be less problematic after surgery and RT dryness 
of mouth and sticky saliva are a more permanent problem and need 
further attention. 
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